Is your child displaying symptoms of ADHD?
A Multicenter, Dose-Optimized, Randomized, Double-Blind, Efficacy and Safety Study with Azstarys® in Children 4 to 12 Years of Age with Attention-Deficit/Hyperactivity Disorder.
- The study is to treat children with ADHD
- ADHD occurs in 6% to 8% of children worldwide
- The goal of the study medication is to alleviate ADHD symptoms with the primary symptoms being inattention, hyperactivity, and impulsivity.
- Study medication is a capsule taken daily and is already approved in children 6 to 12 years old as well as adolescents.
- Has been shown to improve ADHD symptoms in multiple studies.
- There is an option to enroll in a 12-month open label extension (if qualified).
- Close medical care while participating in the trial.
Study Participant Criteria :
- 4 to 5 years of age
- Cannot have been on amphetamines at any time.
- Cannot be on any other ADHD medication during the study.
- Subject must meet criteria for primary diagnosis of ADHD according to the DSM-V
Study Participant Expectations:
- Treatment period of 5 weeks with weekly clinic visits
- Daily oral medication
- Compensation for time and travel
“Did You Know”
- ADHD symptoms affect school performance, extracurricular activities, and home activities.
- ADHD is theorized to result from a deficiency of neurotransmission of dopamine and norepinephrine either through the insufficient sensitivity of the receptors or amount of dopamine produced